세계의 인지기능 및 기억력 향상제 시장 : 제품별, 용도별, 지역별(2025-2033년)

The global cognitive and memory enhancer drugs market size reached USD 6,171.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 9,460.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.86% during 2025-2033. The growing prevalence of cognitive disorders, increasing research and development (R&D) activities to explore new compounds and formulations, and introduction of novel drugs and innovative delivery methods represent some of the key factors driving the market.

Cognitive and memory enhancer drugs, also known as nootropics or smart drugs, aim to improve cognitive function like memory, attention, creativity, and overall mental performance. These drugs are designed to enhance brain activity and promote better cognitive abilities. They are available by prescription for specific medical conditions and can be purchased over the counter (OTC) or online as dietary supplements. They enhance alertness and focus by increasing the release of certain neurotransmitters in the brain. They also boost acetylcholine levels, which is important for memory and learning. They act as antioxidants or anti-inflammatory agents, protecting the brain from damage and promoting optimal brain function. They can also promote clearer thinking and improve cognitive processing speed and lead to better decision-making abilities. They assist in improving short-term and long-term memory, which makes it easier to recall and retain information. They also aid in enhancing academic or work performance by increasing productivity, efficiency, and cognitive abilities.

Cognitive and Memory Enhancer Drugs Market Trends:

At present, the rising prevalence of cognitive disorders, such as Alzheimer's disease, dementia, and attention deficit hyperactivity disorder (ADHD), represents one of the key factors supporting the growth of the market. Besides this, people are becoming more proactive in taking care of their brain health and seeking ways to enhance their cognitive abilities, which is catalyzing the demand for cognitive and memory enhancer drugs. Moreover, increasing research and development (R&D) activities to explore new compounds and formulations that can enhance cognitive functions and memory is propelling the growth of the market. In line with this, the development of novel drugs and innovative delivery methods is expanding the range of options available to consumers, which is strengthening the growth of the market. In addition, the growing demand for drugs that can alleviate age-related cognitive decline and memory loss due to the rising elderly population is offering a favorable market outlook. Apart from this, the increasing adoption of cognitive and memory enhancer drugs among students and professionals seeking improved academic and professional performance is creating lucrative growth opportunities for industry investors. Additionally, the wide availability of cognitive and memory enhancer drugs through online and offline distribution channels is strengthening the growth of the market.

Key Market Segmentation:

Product Insights:

• Aricept
• Exelon
• Namenda
• Razadyne
• Provigil
• Ritalin
• Adderall
• Others

Application Insights:

• Disease Treatment
• Athletic Performance
• Academic Performance
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cognitive and memory enhancer drugs. Some of the factors driving the North America cognitive and memory enhancer drugs market included the growing elderly population, increasing need to enhance focus, memory, and overall cognitive abilities, development of novel drugs, etc.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global cognitive and memory enhancer drugs market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Biogen Inc., Eisai Co Ltd., Novartis AG, Takeda Pharmaceutical Company Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global cognitive and memory enhancer drugs market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global cognitive and memory enhancer drugs market?
• What is the impact of each driver, restraint, and opportunity on the global cognitive and memory enhancer drugs market?
• What are the key regional markets?
• Which countries represent the most attractive cognitive and memory enhancer drugs market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the cognitive and memory enhancer drugs market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the cognitive and memory enhancer drugs market?
• What is the competitive structure of the global cognitive and memory enhancer drugs market?
• Who are the key players/companies in the global cognitive and memory enhancer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cognitive and Memory Enhancer Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Aricept
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Exelon
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Namenda
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Razadyne
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Provigil
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Ritalin
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Adderall
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Application

• 7.1 Disease Treatment
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Athletic Performance
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Academic Performance
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

• 9.1 Overview
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 AbbVie Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Biogen Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Eisai Co Ltd.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Novartis AG
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Takeda Pharmaceutical Company Ltd.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.